Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)

• ClinicalTrials.gov Identifier: NCT02399085
• Recruitment Status: Completed
• First Posted: March 26, 2015
• Results First Posted: February 5, 2020
• Last Update Posted: October 23, 2023
• Sponsor: MorphoSys AG
• Information provided by (Responsible Party): MorphoSys AG

Tracking Information

• First Submitted Date: March 13, 2015
• First Posted Date: March 26, 2015
• Results First Submitted Date: November 27, 2019
• Results First Posted Date: February 5, 2020
• Last Update Posted Date: October 23, 2023
• Actual Study Start Date: March 29, 2016
• Actual Primary Completion Date: November 14, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 28, 2023)

Number of Participants With Best Objective Response Rate (ORR) [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]

ORR = complete response [CR] + partial response [PR]; Independent Radiology/Clinical Review Committee (IRC) Evaluation. ORR after MOR00208 and Lenalidomide combination therapy assessed by the IRC evaluation. ORR was defined as the number of participants of the total number of participants treated with MOR00208 + LEN with CR or PR as best response achieved at any time during the study.

• Original Primary Outcome Measures (submitted: March 25, 2015): Objective response rate (ORR = complete response [CR] + partial response [PR]) [ Time Frame: 3 years ]

Current Secondary Outcome Measures (submitted: September 28, 2023)

• Duration of Response (DoR) by IRC Evaluation [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  DoR [months] = (date of assessment of tumor progression or death - date of assessment of first documented response of (CR or PR) + 1)/30.4375.
• DoR by Investigator (INV) Evaluation [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  DoR [months] = (date of assessment of tumour progression or death - date of assessment of first documented response of (CR or PR) + 1)/30.4375.
• Progression-free Survival (PFS) by IRC Evaluation [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  PFS time was defined as the time (in months) from the date of the first administration of any study drug to the date of tumor progression or death from any cause.
• PFS by INV Evaluation [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  PFS time was defined as the time (in months) from the date of the first administration of any study drug to the date of tumor progression or death from any cause.
• Overall Survival (OS) [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  OS was defined as the time from the date of the first administration of any study drug until death from any cause (documented by the date of death).
• Disease Control Rate (DCR) by IRC Evaluation [ Time Frame: Approximately 2.5 years after first participant enrolled ]
  DCR = CR + PR + SD (Stable disease); IRC Evaluation DCR was defined as the number of participants having CR, PR or SD based on the best objective response achieved at any time during the study.
• DCR by INV Evaluation [ Time Frame: Approximately 2.5 years after first participant enrolled ]
  DCR = CR + PR + SD (Stable disease); IRC Evaluation DCR was defined as the number of participants having CR, PR or SD based on the best objective response achieved at any time during the study.
• Time to Progression (TTP) by IRC Evaluation [ Time Frame: Approximately 2.5 years after first participant enrolled ]
  TTP is defined as the time from the first administration of any study drug until documented DLBCL progression or death as a result of lymphoma.
• TTP by INV Evaluation [ Time Frame: Approximately 2.5 years after first participant enrolled ]
  TTP is defined as the time from the first administration of any study drug until documented DLBCL progression or death as a result of lymphoma.
• Time to Next Treatment (TTNT) [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  Kaplan-Meier analysis of TTNT in FAS population. TTNT is defined as the time from the first administration of any study drug to the institution of next anti-neoplastic therapy (for any reason including disease progression, treatment toxicity and participant preference) or death of any cause, whatever comes first.
• Event-free Survival (EFS) by IRC Evaluation [ Time Frame: Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled ]
  EFS is defined as the time (in months) from the date of the first administration of any study drug to the date of tumour progression, first initiation of a new non-study anti-neoplastic therapy or death from any cause whichever comes first.
• Serum Drug Levels of MOR00208 [ Time Frame: Cycle 1 Days 1, 4, 15 predose and 1 hr post-dose; Cycle 2 Days 1, 15 predose and 1 hr post-dose; Cycle 3 Days 1, 15 predose and 1 hr post-dose; Cycles 4, 5, 6, 7, 9, 11,13, 15, 17, 19, 21, 23 Day 1 predose; End of Treatment ]
  The pharmacokinetics (PK) profile of MOR00208 was investigated by quantifying serum drug levels at baseline and after repeated IV administrations for up to 24 treatment cycles using sparse sampling. MOR00208 PK sample was taken pre-dose and 1 hour ± 10 min after the end of MOR00208 infusion for Cycle 1 to Cycle 23. MOR00208 PK sample (pre-dose only) were taken in odd numbered additional treatment cycles only (e.g., treatment Cycles 13, 15,17, 19, 21, 23).
• Number of Participants Who Developed Anti-MOR00208 Antibodies [ Time Frame: Baseline, Up to a maximum of 23 cycles. ]
  The Anti-MOR00208 Antibodies were investigated by quantifying serum drug levels at baseline and after repeated intravenous (IV) administrations planned for up to 24 treatment cycles using sparse sampling. Anti-MOR00208 antibody sample (pre-dose only) were taken in odd numbered additional treatment cycles only (e.g., treatment Cycles 13, 15,17, 19, 21,23).
• Number of Participants That Experienced Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Approximately 6.5 years after first participant enrolled ]
  TEAEs are defined as any adverse event reported in the following time interval (including the lower and upper limits): date of first administration of study treatment; date of last administration of study treatment + 30 days, or if they are considered to be related to the study drug.
• Severity of Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Approximately 6.5 years after first participant enrolled ]
  Number of participants with Severity of TEAEs during MOR00208 and LEN combination therapy.

Original Secondary Outcome Measures (submitted: March 25, 2015)

• Disease control rate (DCR) [ Time Frame: 3 years ]
  DCR = CR + PR + SD
• Duration of response (DoR) [ Time Frame: 3 years ]
• Progression-free survival (PFS) [ Time Frame: 3 years ]
• Overall survival (OS) [ Time Frame: 3 years ]
• Time to progression (TTP) [ Time Frame: 3 years ]
• Time to next treatment (TTNT) [ Time Frame: 3 years ]
  TTNT is defined as the time from study entry (= first dosing) to the institution of next therapy for any reason including disease progression, treatment toxicity and patient preference. TTNT will be descriptively analysed.
• Safety of LEN combined with MOR00208 according to the frequency and severity of adverse events (AEs) [ Time Frame: 2 years ]
  Safety profile is assessed according to the frequency and severity of adverse events (AEs)
• Potential immunogenicity of MOR00208 [ Time Frame: 2 years ]
  The absolute number and percentage of patients, who develop anti-MOR00208 antibodies, and the results of semi-quantitative anti-MOR00208 antibody titre determinations of confirmed positive sample assessments will be tabulated
• Pharmacokinetics (PK) of MOR00208 [ Time Frame: 2 years ]
  maximum serum concentration [Cmax]
• Pharmacokinetics (PK) of MOR00208 [ Time Frame: 2 years ]
  time to maximum serum concentration [tmax]
• Pharmacokinetics (PK) of MOR00208 [ Time Frame: 2 years ]
  apparent trough serum concentration before dosing [Cpd]
• Pharmacokinetics (PK) of MOR00208 [ Time Frame: 2 years ]
  area under the serum concentration versus time curve from time 0 to the time t of the last quantifiable concentration [AUC0-t]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
• Official Title: A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
• Brief Summary: This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).

Detailed Description

The aim of this single-arm, multicentre, open-label Phase II study is to evaluate the Lenalidomide (LEN) combined with Tafasitamab (MOR00208) in adult participants with DLBCL who had relapsed after or were refractory to at least one, but no more than three previous systemic regimens administered for the treatment of their DLBCL and who were not candidates for high-dose chemotherapy and subsequent Autologous stem cell transplants and were thus considered to have exhausted their therapeutic options. One prior therapy line had to include an anti-CD20 targeted therapy (e.g., rituximab [RTX]).

MOR00208 and LEN were administered for up to 12 cycles (28 days each), followed by MOR00208 monotherapy until progression, in participants with at least stable disease or a better response.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Diffuse Large B-cell Lymphoma

Intervention

• Drug: Tafasitamab
  12 mg/kg
  Other Name: MOR00208
• Drug: Lenalidomide
  25 mg
  Other Names:

  • LEN
  • Revlimid®

Study Arms

Experimental: Tafasitamab (MOR00208) + lenalidomide (LEN)

MOR00208:

MOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.

Additionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.

LEN:

Participants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.

On days when both study drugs were given together, LEN was administered prior to MOR00208.

Interventions:

• Drug: Tafasitamab
• Drug: Lenalidomide

Publications *

• Salles G, Duell J, Gonzalez Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.
• Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, Andre M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958.
• Duell J, Obr A, Augustin M, Endell J, Liu H, Geiger S, Silverman IM, Ambarkhane S, Rosenwald A. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leuk Lymphoma. 2022 Feb;63(2):468-472. doi: 10.1080/10428194.2021.1986219. Epub 2021 Nov 15. No abstract available.
• Cherng HJ, Westin JR. Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls. Clin Cancer Res. 2022 Sep 15;28(18):3908-3910. doi: 10.1158/1078-0432.CCR-22-1626.
• Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.
• Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, Meli E, Fowler NH, Salles G, Feinberg B, Kurukulasuriya NC, Tillmanns S, Parche S, Dey D, Fingerle-Rowson G, Ambarkhane S, Winderlich M, Nowakowski GS. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2021 Nov 15;27(22):6124-6134. doi: 10.1158/1078-0432.CCR-21-1471. Epub 2021 Aug 25.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 5, 2017): 81
• Original Estimated Enrollment (submitted: March 25, 2015): 80
• Actual Study Completion Date: April 19, 2023
• Actual Primary Completion Date: November 14, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Major Inclusion Criteria:

1. Age >18 years
2. Histologically confirmed diagnosis of DLBCL
3. Tumour tissue for central pathology review and correlative studies had to be provided.

4. Participants must had:

   • relapsed and/or refractory disease
   • at least one bidimensionally measurable, PET positive disease site (transverse diameter of ≥1.5 cm and perpendicular diameter of ≥1.0 cm at baseline)
   • received at least one, but no more than three previous systemic regimens for the treatment of DLBCL and one therapy line must had included a CD20-targeted therapy
   • Eastern Cooperative Oncology Group 0 to 2
5. Participants were not considered in the opinion of the investigator eligible, or participants unwilling to undergo intensive salvage therapy including ASCT

6. Participants had to meet the following laboratory criteria at screening:

   • absolute neutrophil count ≥1.5 × 10˄9/L
   • platelet count ≥90 × 10˄9/L
   • total serum bilirubin ≤2.5 × ULN or ≤5 × ULN in cases of Glibert's Syndrome or liver involvement by lymphoma
   • alanine transaminase, aspartate aminotransferase and alkaline phosphatase ≤3 × ULN or <5 × ULN in cases of liver involvement
   • serum creatinine clearance ≥60 mL/minute

7. Females of childbearing potential (FCBP) must:

   • not be pregnant
   • refrain from breastfeeding and donating blood or oocytes
   • agreed to ongoing pregnancy testing
   • committed to continued abstinence from heterosexual intercourse, or agree to use and be able to comply with the use of double-barrier contraception

8. Males (if sexually active with a FCBP) had to

   • use an effective barrier method of contraception
   • refrain from donating blood or sperm

9. In the opinion of the investigator the participants had to:

   • be able and willing to receive adequate prophylaxis and/or therapy for thromboembolic events
   • be able to understand, give written informed consent and comply with all study-related procedures, medication use, and evaluations
   • had no history of noncompliance in relation to medical regimens or not be considered potentially unreliable and/or uncooperative
   • be able to understand the reason for complying with the special conditions of the pregnancy prevention risk management plan and gave written acknowledgement of this.

Major Exclusion Criteria:

1. Participants who had:

   • other histological type of lymphoma
   • primary refractory DLBCL
   • a history of "double/triple hit" genetics

2. Participants who had, within 14 days prior to Day 1 dosing:

   • not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy
   • underwent major surgery or suffered from significant traumatic injury
   • received live vaccines.
   • required parenteral antimicrobial therapy for active, intercurrent infections

3. Participants who:

   • had, in the opinion of the investigator, not recovered sufficiently from the adverse toxic effects of prior therapies
   • were previously treated with CD19-targeted therapy or immunomodulatory drugs (IMiDs)® (e.g., thalidomide, LEN)
   • had a history of hypersensitivity to compounds of similar biological or chemical composition to MOR00208, IMiDs® and/or the excipients contained in the study drug formulations
   • had undergone ASCT within the period ≤ 3 months prior to the signing of the Informed Consent Form. Patients who had a more distant history of ASCT had to exhibit full haematological recovery before enrolment into the study
   • had undergone previous allogenic stem cell transplantation
   • had a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or were at a high risk for a thromboembolic event in the opinion of the investigator and who were not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
   • concurrently used other anti-cancer or experimental treatments
4. Prior history of malignancies other than DLBCL, unless the participant had been free of the disease for ≥5 years prior to screening.

5. Participants with:

   • positive hepatitis B and/or C serology.
   • known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)
   • CNS lymphoma involvement
   • history or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromised the participant's ability to give informed consent.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States
• Removed Location Countries: Czech Republic

Administrative Information

• NCT Number: NCT02399085
• Other Study ID Numbers: MOR208C203; 2014-004688-19 ( EudraCT Number )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: MorphoSys AG
• Original Responsible Party: Same as current
• Current Study Sponsor: MorphoSys AG
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Johannes Duell, MD; MorphoSys AG

• PRS Account: MorphoSys AG
• Verification Date: September 2023